JP2014530231A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530231A5 JP2014530231A5 JP2014535166A JP2014535166A JP2014530231A5 JP 2014530231 A5 JP2014530231 A5 JP 2014530231A5 JP 2014535166 A JP2014535166 A JP 2014535166A JP 2014535166 A JP2014535166 A JP 2014535166A JP 2014530231 A5 JP2014530231 A5 JP 2014530231A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- container
- mdi
- metered dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (15)
- 界面活性剤を含まない医薬組成物であって、
(a)硫酸サルブタモールからなる薬物成分と、
(b)1,1−ジフルオロエタン(R−152a)から実質的になる噴射剤成分と、
から実質的になる、医薬組成物。 - 極性賦形剤を含まない、請求項1に記載の医薬組成物。
- エタノールを含まない、請求項1に記載の医薬組成物。
- 前記噴射剤成分が完全にR−152aからなる、請求項1〜3のいずれか一項に記載の医薬組成物。
- 完全に成分(a)及び(b)からなる、請求項1〜4のいずれか一項に記載の医薬組成物。
- 請求項1〜5のいずれか一項に記載の医薬組成物を含む、密封容器。
- 定量噴霧式吸入器(MDI)と共に使用するための加圧容器である、請求項6に記載の密封容器。
- 請求項7に記載の加圧容器を装着した、定量噴霧式吸入器(MDI)。
- 硫酸サルブタモールからなる薬物成分と、1,1−ジフルオロエタン(R−152a)から実質的になる噴射剤成分の、呼吸器疾患を患うか又は患う可能性のある患者の治療のための、前記2つの成分から実質的になる、界面活性剤を含まない医薬組成物の製造における使用。
- 前記呼吸器疾患が喘息である、請求項9に記載の使用。
- 前記医薬組成物が定量噴霧式吸入器(MDI)を使用して患者に送達されるように適合されてなる、請求項9又は10に記載の使用。
- 呼吸器疾患を患うか又は患う可能性のある患者の治療に用いるための、請求項1〜5のいずれか一項に記載の医薬組成物。
- 前記呼吸器疾患が喘息である、請求項12に記載の医薬組成物。
- 前記医薬組成物が定量噴霧式吸入器(MDI)を使用して患者に送達されるように適合されてなる、請求項12又は13に記載の医薬組成物。
- 請求項1〜5のいずれか一項に記載の医薬組成物の製造方法であって、
薬剤送達装置を使用して前記薬物成分が最終的にエアロゾルスプレーとして放出されることになる開放容器に、秤量した前記薬物成分を導入する工程と、
前記容器にバルブ装置を装着する工程と、
加圧下で前記バルブを通して前記容器に前記噴射剤成分を液形態で導入する工程と、
を含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201117621A GB201117621D0 (en) | 2011-10-12 | 2011-10-12 | Compositions |
GB1117621.1 | 2011-10-12 | ||
PCT/GB2012/052542 WO2013054135A1 (en) | 2011-10-12 | 2012-10-12 | Compositions comprising salbutamol sulphate |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014530231A JP2014530231A (ja) | 2014-11-17 |
JP2014530231A5 true JP2014530231A5 (ja) | 2014-12-25 |
JP5818290B2 JP5818290B2 (ja) | 2015-11-18 |
Family
ID=45091933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014535166A Active JP5818290B2 (ja) | 2011-10-12 | 2012-10-12 | 硫酸サルブタモールを含有する組成物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9114164B2 (ja) |
EP (1) | EP2766005B1 (ja) |
JP (1) | JP5818290B2 (ja) |
CN (1) | CN103857388B (ja) |
AU (1) | AU2012322453B2 (ja) |
BR (1) | BR112014008609B1 (ja) |
CA (1) | CA2851764C (ja) |
ES (1) | ES2556585T3 (ja) |
GB (1) | GB201117621D0 (ja) |
MX (1) | MX336225B (ja) |
WO (1) | WO2013054135A1 (ja) |
ZA (1) | ZA201402234B (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
EP3236967B1 (en) | 2014-12-22 | 2019-10-16 | SUDA Pharmaceuticals Ltd | Prevention and treatment of metastatic disease in thrombocytotic cancer patients |
GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
EP3701940A1 (en) | 2015-12-04 | 2020-09-02 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition |
CN114712337A (zh) * | 2016-09-19 | 2022-07-08 | 墨西哥氟石股份公司 | 药物组合物 |
CA3037080C (en) * | 2016-09-19 | 2021-05-18 | Mexichem Fluor S.A. De C.V. | Stable pharmaceutical compositions comprising indacaterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis) |
ES2957459T3 (es) | 2016-09-19 | 2024-01-19 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende glicopirrolato |
AU2017328910B2 (en) * | 2016-09-19 | 2020-04-09 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
GB2573297A (en) * | 2018-04-30 | 2019-11-06 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
FR3130554A1 (fr) | 2021-12-20 | 2023-06-23 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
FR3137830A1 (fr) | 2022-07-13 | 2024-01-19 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
US5439670A (en) | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
US7105152B1 (en) * | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
DK0617610T3 (da) * | 1991-12-18 | 1997-10-06 | Minnesota Mining & Mfg | Suspensionsaerosolformuleringer. |
ATE236617T1 (de) | 1994-12-22 | 2003-04-15 | Astrazeneca Ab | Aerosol-arzneiformulierungen |
ES2276736T3 (es) | 1995-04-14 | 2007-07-01 | Smithkline Beecham Corporation | Inhalador medidor de dosis para propionato de flucticasona. |
EP1019020A1 (en) | 1997-09-29 | 2000-07-19 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
PT1102579E (pt) | 1998-08-04 | 2003-07-31 | Jago Res Ag | Formulacoes de aerossol medicinais |
GB2392915B (en) | 1999-09-11 | 2004-04-28 | Glaxo Group Ltd | Pharmaceutical formulation of fluticasone propionate |
US6432415B1 (en) | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
CN1144582C (zh) | 2000-11-28 | 2004-04-07 | 中国药科大学 | 治疗呼吸系统疾病的无氟里昂药用气雾剂 |
CN1216600C (zh) * | 2002-04-24 | 2005-08-31 | 信谊药厂 | 盐酸左旋沙丁胺醇气雾剂及制备工艺 |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
GB0323685D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
GB0323684D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
WO2006004646A1 (en) | 2004-06-28 | 2006-01-12 | Nektar Therapeutics | Aerosol formulation comprising nicotine salt |
WO2007020204A2 (en) | 2005-08-12 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate |
GB0915106D0 (en) | 2009-08-28 | 2009-10-07 | Glaxo Group Ltd | Process |
-
2011
- 2011-10-12 GB GB201117621A patent/GB201117621D0/en not_active Ceased
-
2012
- 2012-10-12 WO PCT/GB2012/052542 patent/WO2013054135A1/en active Application Filing
- 2012-10-12 MX MX2014004364A patent/MX336225B/es unknown
- 2012-10-12 US US14/351,001 patent/US9114164B2/en active Active
- 2012-10-12 CN CN201280049813.9A patent/CN103857388B/zh active Active
- 2012-10-12 BR BR112014008609-5A patent/BR112014008609B1/pt active IP Right Grant
- 2012-10-12 AU AU2012322453A patent/AU2012322453B2/en active Active
- 2012-10-12 JP JP2014535166A patent/JP5818290B2/ja active Active
- 2012-10-12 ES ES12787053.3T patent/ES2556585T3/es active Active
- 2012-10-12 EP EP12787053.3A patent/EP2766005B1/en active Active
- 2012-10-12 CA CA2851764A patent/CA2851764C/en active Active
-
2014
- 2014-03-26 ZA ZA2014/02234A patent/ZA201402234B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014530231A5 (ja) | ||
JP2014528470A5 (ja) | ||
Stein et al. | The history of therapeutic aerosols: a chronological review | |
JP2007106777A5 (ja) | ||
HRP20140582T4 (hr) | Kombinacijska terapija za copd | |
CN106455705A (zh) | 用于吸烟欲望救济的方法和装置 | |
JP2009503104A5 (ja) | ||
JP2009269923A5 (ja) | ||
AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
MX336225B (es) | Composiciones que comprenden sulfato de salbutamol. | |
JP2013544781A5 (ja) | ||
WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
MX335944B (es) | Composiciones que comprenden sulfato de salbutamol. | |
HRP20140550T1 (hr) | Aerosolna formulacija za copd | |
WO2009112274A3 (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
TR201000680A2 (tr) | Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler | |
PH12014502746A1 (en) | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same | |
NZ599900A (en) | Pharmaceutical suspension aerosol formulations for use in metered dose inhalers | |
WO2012040228A3 (en) | Aerosol composition for administering drugs | |
MX370890B (es) | Composición que comprende sulfato de salbutamol. | |
PH12014502662A1 (en) | Novel dosage form and formulation of abediterol | |
GB201118188D0 (en) | Manufacture of medicinal aerosol canisters | |
WO2011061498A3 (en) | Inhalation solutions | |
JP2004529108A5 (ja) |